Development of DNA Vaccine Candidate against SARS-CoV-2
Despite the existence of various types of vaccines and the involvement of the world’s leading pharmaceutical companies, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains the most challenging health threat in this century. Along with the increased transmissibility, new strains cont...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/14/5/1049 |
| _version_ | 1827665894201884672 |
|---|---|
| author | Xingyun Wang Nino Rcheulishvili Jie Cai Cong Liu Fengfei Xie Xing Hu Nuo Yang Mengqi Hou Dimitri Papukashvili Yunjiao He Peng George Wang |
| author_facet | Xingyun Wang Nino Rcheulishvili Jie Cai Cong Liu Fengfei Xie Xing Hu Nuo Yang Mengqi Hou Dimitri Papukashvili Yunjiao He Peng George Wang |
| author_sort | Xingyun Wang |
| collection | DOAJ |
| description | Despite the existence of various types of vaccines and the involvement of the world’s leading pharmaceutical companies, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains the most challenging health threat in this century. Along with the increased transmissibility, new strains continue to emerge leading to the need for more vaccines that would elicit protectiveness and safety against the new strains of the virus. Nucleic acid vaccines seem to be the most effective approach in case of a sudden outbreak of infection or the emergence of a new strain as it requires less time than any conventional vaccine development. Hence, in the current study, a DNA vaccine encoding the trimeric prefusion-stabilized ectodomain (S1+S2) of SARS-CoV-2 S-protein was designed by introducing six additional prolines mutation, termed HexaPro. The three-dose regimen of designed DNA vaccine immunization in mice demonstrated the generation of protective antibodies. |
| first_indexed | 2024-03-10T01:36:24Z |
| format | Article |
| id | doaj.art-5de4e2715f04490aa9eed7589350b580 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T01:36:24Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-5de4e2715f04490aa9eed7589350b5802023-11-23T13:32:26ZengMDPI AGViruses1999-49152022-05-01145104910.3390/v14051049Development of DNA Vaccine Candidate against SARS-CoV-2Xingyun Wang0Nino Rcheulishvili1Jie Cai2Cong Liu3Fengfei Xie4Xing Hu5Nuo Yang6Mengqi Hou7Dimitri Papukashvili8Yunjiao He9Peng George Wang10Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaDespite the existence of various types of vaccines and the involvement of the world’s leading pharmaceutical companies, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains the most challenging health threat in this century. Along with the increased transmissibility, new strains continue to emerge leading to the need for more vaccines that would elicit protectiveness and safety against the new strains of the virus. Nucleic acid vaccines seem to be the most effective approach in case of a sudden outbreak of infection or the emergence of a new strain as it requires less time than any conventional vaccine development. Hence, in the current study, a DNA vaccine encoding the trimeric prefusion-stabilized ectodomain (S1+S2) of SARS-CoV-2 S-protein was designed by introducing six additional prolines mutation, termed HexaPro. The three-dose regimen of designed DNA vaccine immunization in mice demonstrated the generation of protective antibodies.https://www.mdpi.com/1999-4915/14/5/1049DNA vaccineCOVID-19SARS-CoV-2 |
| spellingShingle | Xingyun Wang Nino Rcheulishvili Jie Cai Cong Liu Fengfei Xie Xing Hu Nuo Yang Mengqi Hou Dimitri Papukashvili Yunjiao He Peng George Wang Development of DNA Vaccine Candidate against SARS-CoV-2 Viruses DNA vaccine COVID-19 SARS-CoV-2 |
| title | Development of DNA Vaccine Candidate against SARS-CoV-2 |
| title_full | Development of DNA Vaccine Candidate against SARS-CoV-2 |
| title_fullStr | Development of DNA Vaccine Candidate against SARS-CoV-2 |
| title_full_unstemmed | Development of DNA Vaccine Candidate against SARS-CoV-2 |
| title_short | Development of DNA Vaccine Candidate against SARS-CoV-2 |
| title_sort | development of dna vaccine candidate against sars cov 2 |
| topic | DNA vaccine COVID-19 SARS-CoV-2 |
| url | https://www.mdpi.com/1999-4915/14/5/1049 |
| work_keys_str_mv | AT xingyunwang developmentofdnavaccinecandidateagainstsarscov2 AT ninorcheulishvili developmentofdnavaccinecandidateagainstsarscov2 AT jiecai developmentofdnavaccinecandidateagainstsarscov2 AT congliu developmentofdnavaccinecandidateagainstsarscov2 AT fengfeixie developmentofdnavaccinecandidateagainstsarscov2 AT xinghu developmentofdnavaccinecandidateagainstsarscov2 AT nuoyang developmentofdnavaccinecandidateagainstsarscov2 AT mengqihou developmentofdnavaccinecandidateagainstsarscov2 AT dimitripapukashvili developmentofdnavaccinecandidateagainstsarscov2 AT yunjiaohe developmentofdnavaccinecandidateagainstsarscov2 AT penggeorgewang developmentofdnavaccinecandidateagainstsarscov2 |